Get the Stockscreener App
2.12
0.93%
-0.02
After Hours:
2.07
-0.05
-2.36%
Acumen Pharmaceuticals Inc stock is traded at $2.12, with a volume of 437.42K.
It is down -0.93% in the last 24 hours and up +60.61% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$2.14
Open:
$2.14
24h Volume:
437.42K
Relative Volume:
1.07
Market Cap:
$128.42M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.8929
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+9.28%
1M Performance:
+60.61%
6M Performance:
+90.99%
1Y Performance:
-9.79%
1-Day Range:
$2.07
$2.20
1-Week Range:
$1.82
$2.35
52-Week Range:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.12 | 129.63M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Tools to monitor Acumen Pharmaceuticals Inc. recovery probability2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
Acumen Pharmaceuticals Inc. stock retracement – recovery analysisTrade Analysis Summary & Weekly Top Performers Watchlists - newser.com
Long term hold vs stop loss in Acumen Pharmaceuticals Inc.Gold Moves & Long-Term Growth Portfolio Plans - newser.com
What to do if you’re stuck in Acumen Pharmaceuticals Inc.2025 Price Momentum & Target Return Focused Stock Picks - newser.com
What the charts say about Acumen Pharmaceuticals Inc. todayQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - newser.com
Is Acumen Pharmaceuticals Inc. stock a top pick in earnings season2025 Winners & Losers & Low Risk Investment Opportunities - newser.com
Relative strength of Acumen Pharmaceuticals Inc. in sector analysisAnalyst Upgrade & Technical Pattern Based Signals - newser.com
How Acumen Pharmaceuticals Inc. stock reacts to oil prices2025 Retail Activity & Free Real-Time Market Sentiment Alerts - newser.com
Central Nervous System Biomarkers Market Growth & Industry - openPR.com
What analysts say about Acumen Pharmaceuticals Inc stockMomentum Trading Signals & Stay One Step Ahead of Risk Events - earlytimes.in
Institutional scanner results for Acumen Pharmaceuticals Inc.Quarterly Profit Report & Risk Managed Investment Entry Signals - newser.com
Trend analysis for Acumen Pharmaceuticals Inc. this weekWeekly Profit Recap & AI Driven Price Forecasts - newser.com
Published on: 2025-10-05 05:00:14 - newser.com
Will Acumen Pharmaceuticals Inc. stock return to pre crisis levelsJuly 2025 News Drivers & Safe Swing Trade Setup Alerts - newser.com
Is it time to cut losses on Acumen Pharmaceuticals Inc.July 2025 Trends & Verified Momentum Watchlists - newser.com
Promising Penny Stocks To Watch In September 2025 - Yahoo Finance
Analyzing net buyer seller activity in Acumen Pharmaceuticals Inc.July 2025 Setups & AI Powered Market Entry Ideas - newser.com
Is Acumen Pharmaceuticals Inc a good long term investmentHigh Dividend Yield Stocks & Outstanding Capital Tips - earlytimes.in
Acumen Pharmaceuticals, Inc. $ABOS Shares Sold by Goldman Sachs Group Inc. - Defense World
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):